View Older Stories View More Recent Stories

Mar 26, 2018 04:30PM Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
Mar 22, 2018 04:32PM Emergent BioSolutions (EBS) to Implement Stock Repurchase Program for up to $50 Million
Mar 22, 2018 04:30PM Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
Mar 22, 2018 04:30PM Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
Feb 28, 2018 06:46AM Emergent BioSolutions (EBS) Secures 1-Yr $26M Contract for Vaccinia Immune Globulin Program
Feb 28, 2018 06:45AM Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
Feb 28, 2018 06:45AM Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
Feb 26, 2018 04:22PM EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
Feb 26, 2018 04:15PM Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
Feb 26, 2018 04:15PM Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
Feb 22, 2018 04:46PM Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results
Feb 22, 2018 04:46PM Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results
Feb 8, 2018 06:30AM Emergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018
Feb 8, 2018 06:30AM Emergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018
Jan 8, 2018 06:35AM Emergent BioSolutions (EBS) Reports Prelim FY17 Revenues Above Prior Guidance; Announces 2018 Revenue Outlook Above Consensus
Jan 8, 2018 06:30AM Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook
Jan 8, 2018 06:30AM Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook
Jan 4, 2018 07:12AM Emergent BioSolutions (EBS) Commences Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
Jan 4, 2018 07:00AM Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
Jan 4, 2018 07:00AM Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
Jan 3, 2018 07:00AM Emergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
Jan 3, 2018 07:00AM Emergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
Dec 12, 2017 07:01AM Emergent BioSolutions (EBS) Secures $8M Contract from Department of National Defense to Supply Anthrasil to Canadian Government
Dec 12, 2017 07:00AM Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
Dec 12, 2017 07:00AM Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
Nov 30, 2017 07:00AM Emergent BioSolutions to Host 2017 Analyst & Investor Day
Nov 20, 2017 07:07AM Emergent BioSolutions (EBS) Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
Nov 20, 2017 07:00AM Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
Nov 14, 2017 05:38PM Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
May 4, 2016 04:15PM Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
Apr 21, 2016 04:15PM Emergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call on May 5, 2016
Feb 11, 2016 07:01AM Emergent BioSolutions to Release Fourth Quarter and Full Year 2015 Financial Results and Conduct a Conference Call on February 25, 2016
Jan 13, 2016 09:46AM Ligand Pharma (LGND), Emergent BioSolutions (EBS) Enter Licensing Agreement Covering OmniAb Platform
Jan 13, 2016 09:45AM Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions
Jan 11, 2016 07:03AM Emergent BioSolutions (EBS) Prelim. FY15 adj.-EPS Tops Views
Jan 11, 2016 07:01AM Emergent Biosolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year (2016-2020) Strategic Growth Plan
Dec 21, 2015 04:15PM Emergent BioSolutions to Participate in First Quarter 2016 Investor Conferences
Oct 22, 2015 07:00AM Emergent BioSolutions to Release Third Quarter 2015 Financial Results and Conduct a Conference Call on November 5, 2015
Sep 24, 2015 09:00AM Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
Jul 23, 2015 07:00AM Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015
Jul 23, 2015 07:00AM Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015
May 21, 2015 09:00AM Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
May 14, 2015 07:00AM Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 21, 2015 at 9:00 AM Eastern; Webcast Will be Available
May 7, 2015 04:28PM Emergent BioSolutions Reports First Quarter 2015 Financial Results
May 7, 2015 04:28PM Emergent BioSolutions Reports First Quarter 2015 Financial Results
Apr 29, 2015 04:01PM Emergent BioSolutions to Participate in May and June 2015 Investor Conferences
Apr 29, 2015 04:01PM Emergent BioSolutions to Participate in May and June 2015 Investor Conferences
Mar 9, 2015 07:00AM Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
Mar 5, 2015 04:01PM Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides Update on 2015 Outlook
Feb 20, 2015 07:00AM Emergent BioSolutions to Participate in March 2015 Investor Conferences
View More Recent Stories View Older Stories